ALX Engine
Licensing Functionally Superior Successors — Before LOE Closes and the Competition Locks You Out
ALX — A Precision Prodrug Engine
ALX — A Precision Prodrug Engine — is a chemistry system that creates new, patentable versions of existing small‑molecule drugs. ALX enables partners to upgrade marketed drugs, strengthen pipeline assets, accelerate successor drug programs, and secure competitive lockout within specific drug classes. ALX licensing provides commercial rights to apply ALX to partner portfolios, while ALX manufacturing licenses govern the synthesis of ALX‑enabled compounds across CDMOs and API manufacturers. The engine operates across multiple therapeutic areas and supports pre‑LOE franchise protection, post‑LOE differentiation, and multi‑program portfolio expansion.
Why These 30 Drugs?
These 30 drugs represent high-value, assay-ready small molecules suitable for ALX feasibility and successor drug creation. They were selected based on conjugation handle accessibility, CRO assay availability, synthetic tractability, ALX‑compatible chemical structure, and strong commercial relevance.
ALX Feasibility Criteria
- ✓Clean conjugation handles
- ✓CRO-available bioassays
- ✓ALX-compatible chemical structure
- ✓Small-molecule linker compatibility (carbamates, carbonates, ureas, esters, short PEG fragments, amino acids, sugars, metabolites)
- ✓Small-molecule X-domains only (no peptides, proteins, polymers, ADC linkers)
- ✓Synthetic tractability
- ✓Coverage under ALX structure rules
All 30 ALX Exemplar Drugs
Successor Drug Strategy
ALX enables partners to create structurally distinct successor drugs before LOE closes. Each ALX variant is a new chemical entity (NCE) with improved PK, exposure, or tolerability, enabling franchise protection and accelerated 505(b)(2) development.